Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 9/20 | 0.47 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12467473 | 0.92 | BTN3A1 (0.45) | BTN3A1PRTN3ANPEPLAP3 | |
| SCHEMBL21158536 | 0.92 | BTN3A1 (0.45) | BTN3A1PRTN3ANPEPLAP3 | |
| SCHEMBL25526279 | 0.90 | TSHR (0.44) | BTN3A1LMNA | |
| SCHEMBL25526275 | 0.90 | TSHR (0.44) | BTN3A1LMNA | |
| SCHEMBL25526266 | 0.90 | TSHR (0.44) | BTN3A1LMNA | |
| SCHEMBL25526243 | 0.90 | TSHR (0.44) | BTN3A1LMNA | |
| SCHEMBL25526288 | 0.90 | TSHR (0.44) | BTN3A1LMNA | |
| SCHEMBL28453863 | 0.90 | TSHR (0.44) | BTN3A1LMNA | |
| SCHEMBL28453865 | 0.90 | TSHR (0.44) | BTN3A1LMNA | |
| SCHEMBL25526272 | 0.90 | TSHR (0.44) | BTN3A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407456-B2 | Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof | QUIMICA SINTETICA, S.A. (ES) | 2019-09-10 | — | — | US | disclosed |
| US-20190185507-A1 | Sofosbuvir Derivatives for the Treatment of Hepatitis C | SANDOZ AG (CH) | 2019-06-20 | — | — | US | disclosed |
| US-20180118776-A1 | NUCLEOSIDE PHOSPHORAMIDATES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS AND PREPARATION THEREOF | QUIMICA SINTETICA S.A. (ES) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185507-A1 | Sofosbuvir Derivatives for the Treatment of Hepatitis C | HAVCR2, ZC3HAV1, GTF3C4 | BTN3A1 2643/4885PRTN3 743/4885LMNA 3860/4885 |
| US-20180118776-A1 | NUCLEOSIDE PHOSPHORAMIDATES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS AND PREPARATION THEREOF | MTAP, PNP, UMPS | BTN3A1 3427/4885PRTN3 1149/4885LMNA 3480/4885 |
| US-10407456-B2 | Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof | MTAP, PNP, UMPS | BTN3A1 3427/4885PRTN3 1149/4885LMNA 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.